Nightingale Health Oyj Past Earnings Performance
Past criteria checks 0/6
Nightingale Health Oyj's earnings have been declining at an average annual rate of -35.3%, while the Healthcare industry saw earnings growing at 3.6% annually. Revenues have been growing at an average rate of 22.9% per year.
Key information
-35.3%
Earnings growth rate
-25.5%
EPS growth rate
| Healthcare Industry Growth | 15.7% |
| Revenue growth rate | 22.9% |
| Return on equity | -20.0% |
| Net Margin | -494.2% |
| Next Earnings Update | 20 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Nightingale Health Oyj makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4 | -18 | 10 | 0 |
| 30 Sep 23 | 4 | -18 | 9 | 0 |
| 30 Jun 23 | 4 | -18 | 9 | 0 |
| 31 Mar 23 | 4 | -18 | 9 | 0 |
| 31 Dec 22 | 3 | -19 | 8 | 0 |
| 30 Sep 22 | 3 | -17 | 7 | 0 |
| 30 Jun 22 | 2 | -16 | 6 | 0 |
| 31 Mar 22 | 2 | -14 | 7 | 0 |
| 31 Dec 21 | 3 | -12 | 8 | 0 |
| 30 Sep 21 | 2 | -11 | 7 | 0 |
| 30 Jun 21 | 2 | -10 | 6 | 0 |
| 31 Mar 21 | 2 | -8 | 0 | 0 |
| 31 Dec 20 | 2 | -5 | 0 | 0 |
| 30 Sep 20 | 2 | -4 | 0 | 0 |
| 30 Jun 20 | 2 | -4 | 0 | 0 |
| 30 Jun 19 | 2 | -4 | 1 | 0 |
| 30 Jun 18 | 2 | -3 | 0 | 0 |
| 30 Jun 17 | 2 | -1 | 0 | 0 |
Quality Earnings: 7XE is currently unprofitable.
Growing Profit Margin: 7XE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7XE is unprofitable, and losses have increased over the past 5 years at a rate of 35.3% per year.
Accelerating Growth: Unable to compare 7XE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7XE is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (30.9%).
Return on Equity
High ROE: 7XE has a negative Return on Equity (-20%), as it is currently unprofitable.